Article
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Aug 2022
Pascual J, Attard G, Bidard F-C, Curigliano G, De Mattos-Arruda L, Diehn M, Italiano A, Lindberg J, Merker J D, Montagut C, Normanno N, Pantel K, Pentheroudakis G, Popat S, Reis-Filho J S, Tie J, Seoane J, Tarazona N, Yoshino T, Turner N C
Abstract excerpt
Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a strong evidence base for use in patients with cancer. The European Society for Medical Oncology convened an expert working group to review the analytical and clinical validity and utility of ctDNA assays. For patients with advanced cancer, validated and adequately sensitive ctDNA assays have utility in identifying actionable...
Topics
Join the communities discussing this publication.